Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Sonoma Pharmaceuticals, Inc. (SNOA)
Price$1.33Cached quote
Net income
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total cash / debt
CashTotal debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $14.3M | $12.7M | $13.3M | $12.6M | $18.6M | $17.9M | $19.0M | $16.7M | $12.8M | $9.4M | $13.9M | $13.7M | $15.5M | $12.7M | $9.8M |
| Gross profit | $7.4M | $5.5M | $4.7M | $4.5M | $4.0M | $6.6M | $8.1M | $8.9M | $7.3M | $5.7M | $2.6M | $7.3M | $8.4M | $10.7M | $8.7M | $6.1M |
| Gross margin | 37.97% | 38.25% | 37.26% | 33.73% | 31.62% | 35.21% | 45.30% | 46.81% | 43.88% | 44.19% | 28.26% | 52.61% | 61.44% | 69.52% | 68.38% | 62.96% |
| Research & development | $2.3M | $1.8M | $1.9M | $207,000 | $125,000 | $555,000 | $1.3M | $1.5M | $1.6M | $1.6M | $1.8M | $1.5M | $2.9M | $2.2M | $2.0M | $2.0M |
| Operating expenses | $9.9M | $9.2M | $9.4M | $9.0M | $9.9M | $10.0M | $15.5M | $20.1M | $21.5M | $18.6M | $17.4M | $13.9M | $14.4M | $14.1M | $15.2M | $13.6M |
| Operating income | −$2.5M | −$3.7M | −$4.7M | −$4.6M | −$5.9M | −$3.4M | −$7.4M | −$11.3M | −$14.2M | −$13.0M | −$14.7M | −$6.7M | −$6.1M | −$3.4M | −$6.5M | −$7.5M |
| Operating margin | −12.60% | −25.97% | −36.91% | −34.43% | −46.62% | −18.51% | −41.22% | −59.35% | −85.18% | −101.16% | −157.05% | −48.07% | −44.27% | −21.84% | −50.75% | −76.94% |
| EBITDA | −$2.3M | −$3.6M | −$4.5M | −$4.4M | −$5.7M | −$3.2M | −$7.1M | −$10.8M | −$13.7M | −$12.7M | −$14.5M | −$6.4M | −$5.8M | −$3.1M | −$6.1M | −$7.1M |
| EBITDA margin | −11.89% | −25.00% | −35.53% | −33.49% | −45.15% | −17.30% | −39.48% | −56.96% | −82.24% | −99.23% | −154.45% | −46.24% | −42.19% | −20.10% | −48.19% | −72.89% |
| Net income | −$3.2M | −$3.5M | −$4.8M | −$5.2M | −$5.1M | −$4.0M | −$3.3M | −$11.8M | −$14.3M | $9.3M | −$10.2M | −$8.2M | $3.7M | −$5.4M | −$7.3M | −$7.9M |
| Net profit margin | −16.26% | −24.20% | −37.97% | −38.81% | −40.28% | −21.20% | −18.45% | −62.19% | −86.01% | 72.31% | −108.46% | −59.21% | 27.33% | −35.15% | −57.51% | −81.48% |
| Basic EPSper basic share | -$1.89 | -$2.79 | -$10.63 | -$30.40 | -$38.40 | -$39.40 | -$44.80 | -$255.40 | -$569.80 | $396.00 | -$556.20 | -$765.00 | $486.00 | -$1,170.00 | -$240.43 | -$270.00 |
| Diluted EPSper diluted share | -$1.89 | -$2.79 | -$10.63 | -$30.40 | -$38.40 | -$39.40 | -$44.80 | -$255.40 | -$569.80 | $396.00 | -$556.20 | -$765.00 | $486.00 | -$1,170.00 | -$240.43 | -$270.00 |
Owners
Reported shareholders
0.85%of listed shares
RENAISSANCE TECHNOLOGIES LLC40.47K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
RENAISSANCE TECHNOLOGIES LLC | 0.85%40.47K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.56%26.79K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.39%18.79K shares |
McKinley Carter Wealth Services, Inc. | 0.23%11.19K shares |
UBS Group AG | 0.16%7.81K shares |
Global Retirement Partners, LLC | 0.05%2.55K shares |
MORGAN STANLEY | 0.04%2K shares |
OSAIC HOLDINGS, INC. | 0.01%500 shares |
BARCLAYS PLC | <0.01%459 shares |
BlackRock, Inc. | <0.01%113 shares |
VANGUARD FIDUCIARY TRUST CO | <0.01%100 shares |
HARBOUR INVESTMENTS, INC. | <0.01%15 shares |
Quaker Wealth Management, LLC | <0.01%3 shares |
DANSKE BANK A/S | <0.01%1 shares |
Percentages use 4.79M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data